Katharina Schindowski

List of Publications by Year
in descending order

41 papers	2,202 citations	279798 23 h-index	302126 39 g-index
46 all docs	46 docs citations	46 times ranked	3240 citing authors

#	Article	IF	Citations
1	Alzheimer's Disease-Like Tau Neuropathology Leads to Memory Deficits and Loss of Functional Synapses in a Novel Mutated Tau Transgenic Mouse without Any Motor Deficits. American Journal of Pathology, 2006, 169, 599-616.	3.8	337
2	Neurotrophic factors in Alzheimerâ€™s disease: role of axonal transport. Genes, Brain and Behavior, 2008, 7, 43-56.	2.2	298
3	Tailoring Formulations for Intranasal Nose-to-Brain Delivery: A Review on Architecture, Physico-Chemical Characteristics and Mucociliary Clearance of the Nasal Olfactory Mucosa. Pharmaceutics, 2018, 10, 116.	4.5	242
4	Early Axonopathy Preceding Neurofibrillary Tangles in Mutant Tau Transgenic Mice. American Journal of Pathology, 2007, 171, 976-992.	3.8	122
5	Passive anti-amyloid immunotherapy in Alzheimer's disease: What are the most promising targets?. Immunity and Ageing, 2013, 10, 18.	4.2	97
6	p25/Cdk5-mediated retinoblastoma phosphorylation is an early event in neuronal cell death. Journal of Cell Science, 2005, 118, 1291-1298.	2.0	93
7	Age-related increase of oxidative stress-induced apoptosis in micePrevention by Ginkgo biloba extract (EGb761). Journal of Neural Transmission, 2001, 108, 969-978.	2.8	81
8	Age-related impairment of human T lymphocytesâ€™ activation: specific differences between CD4+ and CD8+ subsets. Mechanisms of Ageing and Development, 2002, 123, 375-390.	4.6	69
9	Age-related changes of apoptotic cell death in human lymphocytes. Neurobiology of Aging, 2000, 21, 661-670.	3.1	66
10	Reduced antioxidant enzyme activity in brains of mice transgenic for human presenilin-1 with single or multiple mutations. Neuroscience Letters, 2000, 292, 87-90.	2.1	59
11	Alzheimer's Disease-like Alterations in Peripheral Cells from Presenilin-1 Transgenic Mice. Neurobiology of Disease, 2001, 8, 331-342.	4.4	55
12	Regulation of GDF-15, a distant TGF-Î² superfamily member, in a mouse model of cerebral ischemia. Cell and Tissue Research, 2011, 343, 399-409.	2.9	53
13	Early Tau Pathology Involving the Septo-Hippocampal Pathway in a Tau Transgenic Model: Relevance to Alzheimers Disease. Current Alzheimer Research, 2009, 6, 152-157.	1.4	50
14	A comprehensive screening platform for aerosolizable protein formulations for intranasal and pulmonary drug delivery. International Journal of Pharmaceutics, 2017, 532, 537-546.	5.2	50
15	Neurogenesis and cell cycleâ€reactivated neuronal death during pathogenic tau aggregation. Genes, Brain and Behavior, 2008, 7, 92-100.	2.2	48
16	Enhanced ROS-Generation in Lymphocytes from Alzheimerâ€™s Patients. Pharmacopsychiatry, 2005, 38, 312-315.	3.3	47
17	Enlarged infarct volume and loss of BDNF mRNA induction following brain ischemia in mice lacking FGF-2. Experimental Neurology, 2004, 189, 252-260.	4.1	45
18	Improved In Vitro Model for Intranasal Mucosal Drug Delivery: Primary Olfactory and Respiratory Epithelial Cells Compared with the Permanent Nasal Cell Line RPMI 2650. Pharmaceutics, 2019, 11, 367.	4.5	43

#	Article	IF	Citations
19	Increased T-cell Reactivity and Elevated Levels of CD8+ Memory T-cells in Alzheimerâ€™s Disease-patients and T-cell Hyporeactivity in an Alzheimerâ€™s Disease-mouse Model: Implications for Immunotherapy. NeuroMolecular Medicine, 2007, 9, 340-354.	3.4	42
20	Apoptosis of CD4+ T and Natural Killer Cells in Alzheimer's Disease. Pharmacopsychiatry, 2006, 39, 220-228.	3.3	41
21	Loss of Medial Septum Cholinergic Neurons in THY-Tau22 Mouse Model: What Links with tau Pathology?. Current Alzheimer Research, 2011, 8, 633-638.	1.4	38
22	Impact of Aging: Sporadic, and Genetic Risk Factors on Vulnerability to Apoptosis in Alzheimer's Disease. NeuroMolecular Medicine, 2003, 4, 161-178.	3.4	30
23	Nose-to-Brain delivery of insulin for Alzheimerâ€™s disease. ADMET and DMPK, 2015, 3, .	2.1	23
24	First Steps to Develop and Validate a CFPD Model in Order to Support the Design of Nose-to-Brain Delivered Biopharmaceuticals. Pharmaceutical Research, 2016, 33, 1337-1350.	3.5	21
25	Allogenic Fc Domain-Facilitated Uptake of IgG in Nasal Lamina Propria: Friend or Foe for Intranasal CNS Delivery?. Pharmaceutics, 2018, 10, 107.	4.5	21
26	Expression of trkB and trkC receptors and their ligands brainâ€derived neurotrophic factor and neurotrophinâ€3 in the murine amygdala. Journal of Neuroscience Research, 2008, 86, 411-421.	2.9	20
27	Selective CNS Targeting and Distribution with a Refined Region-Specific Intranasal Delivery Technique via the Olfactory Mucosa. Pharmaceutics, 2021, 13, 1904.	4.5	16
28	Nano-in-Micro-Particles Consisting of PLGA Nanoparticles Embedded in Chitosan Microparticles via Spray-Drying Enhances Their Uptake in the Olfactory Mucosa. Frontiers in Pharmacology, 2021, 12, 732954.	3.5	13
29	Is abeta a sufficient biomarker for monitoring anti-abeta clinical studies? A critical review. Frontiers in Aging Neuroscience, 2013, 5, 25.	3.4	12
30	Efficient Construction and Effective Screening of Synthetic Domain Antibody Libraries. Methods and Protocols, 2019, 2, 17.	2.0	12
31	Impact of Glycosylation and Species Origin on the Uptake and Permeation of IgGs through the Nasal Airway Mucosa. Pharmaceutics, 2020, 12, 1014.	4.5	12
32	In vivo manipulation of interleukin-2 expression by a retroviral tetracycline (tet)-regulated system. Cancer Gene Therapy, 1999, 6, 139-146.	4.6	10
33	Establishment of an Olfactory Region-specific Intranasal Delivery Technique in Mice to Target the Central Nervous System. Frontiers in Pharmacology, 2021, 12, 789780.	3.5	9
34	Central Nervous System Delivery of Antibodies and Their Single-Domain Antibodies and Variable Fragment Derivatives with Focus on Intranasal Nose to Brain Administration. Antibodies, 2021, 10, 47.	2.5	8
35	Editorial: Intranasal Drug Delivery: Challenges and Opportunities. Frontiers in Pharmacology, 2022, 13, 868986.	3.5	7
36	Data of rational process optimization for the production of a full IgG and its Fab fragment from hybridoma cells. Data in Brief, 2016, 8, 426-435.	1.0	5

#	Article	IF	Citations
37	Optimized fermentation conditions for improved antibody yield in hybridoma cells. BMC Proceedings, 2013, 7, .	1.6	2
38	Protein aerosol for intranasal nose to brain (N2B) delivery. BMC Proceedings, 2015, 9, .	1.6	2
39	Intravenous immunoglobulin for the treatment of Alzheimer's disease: current evidence and considerations. Degenerative Neurological and Neuromuscular Disease, 2014, 4, 121.	1.3	1
40	Regulation of Neurotrophic Factors During Pathogenic Tau-Aggregation: A Detailed Protocol for Double-Labeling mRNA by In Situ Hybridization and Protein Epitopes by Immunohistochemistry. Methods in Molecular Biology, 2017, 1523, 391-414.	0.9	1
41	Hyaluronate Spreading Validates Mucin-Agarose Analogs as Test Systems to Replace Porcine Nasal Mucosa Explants â€“ an Experimental and Theoretical Investigation. Colloids and Surfaces B: Biointerfaces, 2022, , 112689.	5.0	0